drugset
drugset / Trial / NCT04282278

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

NCT04282278 ↗

Phase 2 Unknown 180 enrolled Hebei Medical University Fourth Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.

Timeline

Start
2020-07-16
Primary completion
2022-04-01
Completion
2024-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Rivoceranib Small molecule 250 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

neoplasm